The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 21, 2026 for Pharmaceutical ....

PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED CIN: U24239MH1991PLC059995 Registered Office: 11/12 Udyog Nagar, S.V. Road, Goregaon West, Mumbai 400 104. Tel: 022- 67607080 E-Mail- pbgil.250191@gmail.com/ gtblmumbai@gtbl.in 21st July, 2026 Corporate Relationship Department Listing Department BSE Limited National Stock Exchange of India Limited Floor 25, Phiroze Jeejeebhoy Towers Exchange Plaza, Bandra Kurla Complex, Dalal Street, Mumbai- 400001 Bandra (East), Mumbai- 400051 Scrip Code – 530199 Symbol: THEMISMED corp.relations@bseindia.com takeover@nse.co.in Gujarat Themis Biosyn Limited Block No. 69-c, GIDC Industrial Estate, Vapi – 396195, Gujarat. cfoassist@themismedicare.com Dear Sir / Madam, Sub: Disclosure under Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 – Indirect Incumbrancer. With reference to the captioned subject, we enclose herewith the disclosure Pursuant to Regulation 31 / applicable provisions of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in respect of the creation of: a) a pledge over 25,24,245 equity shares, constituting 51% of the issued and paid-up share capital of Pharmaceutical Business Group (India) Limited ("PBGIL"); and b) a non-disposal undertaking over 21,57,855 equity shares, constituting 47.98% of the issued and paid-up share capital of PBGIL; by Vividhmargi Investments Private Limited (VIPL) in favour of CTL Trusteeship Limited, acting as Debenture Trustee, pursuant to the Pledge Agreement-cum-Non-Disposal Undertaking dated June 28, 2026, executed in connection with the Debenture Trust Deed dated June 25, 2026. As PBGIL holds 5,12,40,000 equity shares, constituting 47.02% of the equity share capital of Gujarat Themis Biosyn Limited (GTBL or Target), the aforesaid creation of pledge and non-disposal undertaking over the shares of PBGIL would result in an indirect encumbrance over 5,12,40,000 equity shares of the GTBL held by PBGIL. PBGIL is part of promoter group entity. PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED CIN: U24239MH1991PLC059995 Registered Office: 11/12 Udyog Nagar, S.V. Road, Goregaon West, Mumbai 400 104. Tel: 022- 67607080 E-Mail- pbgil.250191@gmail.com/ gtblmumbai@gtbl.in This is for your information and record please. Thanking you, Yours faithfully, For Pharmaceutical Business Group (India) Limited Mrs. Jayshree D. Patel Director Encl.: As above PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED CIN: U24239MH1991PLC059995 Registered Office: 11/12 Udyog Nagar, S.V. Road, Goregaon West, Mumbai 400 104. Tel: 022- 67607080 E-Mail- pbgil.250191@gmail.com/ gtblmumbai@gtbl.in Reg 31(1) – creation of encumbrances / pledge by promoters (file with SE and TC, by Promoters – within 7 working days from encumbrance) Disclosure by the Promoter(s) to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/ release of encumbrance, in terms of Regulation 31(1) and 31(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Creation of encumbrance: 1 Name of the Target Company (TC) Gujarat Themis Biosyn Limited 2 Names of the stock exchanges where the BSE Limited and National Stock Exchange of shares of the target company are listed India Limited 3 Date of reporting 3rd July, 2026 4 Name of the promoter or PAC on whose Indirect encumbrance on Shares in GTBL held shares encumbrance has been created by Pharmaceutical Business Group (India) /released/ invoked Limited, as explained in Note below. 5 Details of the creation of encumbrance: As mentioned below Sr. Name of promoter Promoter holding Promoter holding already (s) or PACs with him in the target company encumbered (2) Number % of total Number % of total (1) (2) (3) (4) (5) (6) 1 Pharmaceutical Business Group 5,12,40,000 47.02 25,50,000 4.98 (India) Limited (PBGIL)* PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED CIN: U24239MH1991PLC059995 Registered Office: 11/12 Udyog Nagar, S.V. Road, Goregaon West, Mumbai 400 104. Tel: 022- 67607080 E-Mail- pbgil.250191@gmail.com/ gtblmumbai@gtbl.in Sr. Details of events pertaining to encumbrance (3) Post event holding of encumbered shares $ (Creation) Type of Date of Type of Reasons Number % of Name of Number % of event creation/ encumbrance for share the entity in total (creation / release/ (pledge/ lien/ encumb- capital whose release / invocation of non disposal rance favor shares invocation) encumbrance undertaking/ ** encumbered others) *** (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) 1 Creation 29/06/2026 Indirect As stated 5,12,40,000 47.02 CTL 5,12,40,000 47.02 encumbrance below Trusteeship Limited Lender: Kotak Credit Opportunities Fund Trust Release of encumbrance: 1 Name of the Target Company (TC) Gujarat Themis Biosyn Limited 2 Names of the stock exchanges where the BSE Limited and National Stock Exchange of shares of the target company are listed India Limited 3 Date of reporting 16th July, 2026 4 Name of the promoter or PAC on whose Indirect encumbrance on Shares in GTBL held shares encumbrance has been created by Pharmaceutical Business Group (India) /released/ invoked Limited, as explained in Note below. 5 Details of the creation of encumbrance: As mentioned below Sr. Name of promoter Promoter holding Promoter holding already (s) or PACs with him in the target company encumbered (2) Number % of total Number % of total (1) (2) (3) (4) (5) (6) 1 Pharmaceutical Business Group 5,12,40,000 47.02% 5,12,40,000 100% (India) Limited (PBGIL)* (Indirect encumbrance) 25,50,000 2.34% (Pledge) PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED CIN: U24239MH1991PLC059995 Registered Office: 11/12 Udyog Nagar, S.V. Road, Goregaon West, Mumbai 400 104. Tel: 022- 67607080 E-Mail- pbgil.250191@gmail.com/ gtblmumbai@gtbl.in Sr. Details of events pertaining to encumbrance (3) Post event holding of encumbered shares $ (Creation) Type of Date of Type of Reasons for Number % of Name of Number % of event creation/ encumbrance encumb- share the entity in total (creation / release/ (pledge/ lien/ rance capital whose release / invocation of non disposal ** favor shares invocation) encumbrance undertaking/ encumbered others) *** (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) 1 Release 08/07/2026 Pledge Repayment 25,45,000 2.33% CTL 5,12,40,000 100% of Loan (Pledge) Trusteeship (Indirect Limited encumbrance) Lender: Kotak 5,000 0.004% Credit (Pledge) Opportunities Fund Trust Indirect encumbrance arising pursuant to (i) pledge over 25,24,245 equity shares and (ii) non-disposal undertaking over 21,57,855 equity shares of Pharmaceutical Business Group (India) Limited. The shareholding represents only Direct pledged shareholding. Indirect encumbrance is not covered in Post event holding of encumbered shares. Therefore the indirect holding of 5,12,40,000 is same before and after pledge release transaction. This disclosure is being made keeping in view indirect encumbrance on shares of the Target. Pharmaceutical Business Group (India) Limited (PBGIL) holds 5,12,40,000 equity shares, constituting 47.02% of the equity share capital of Gujarat Themis Biosyn Limited (GTBL or Target). Vividhmargi Investment Private Limited (VIPL) has created encumbrance on its holding by way of; (i) pledge over 25,24,245 equity shares in PBGIL, and (ii) non-disposal undertaking over 21,57,855 equity shares in PBGIL. Accordingly, said encumbrance on the shares in PBGIL would result in indirect encumbrance on equity shares in GTBL held by PBGIL. # Pursuant to the Debenture Trust Deed and the Pledge Agreement-cum-Non-Disposal Undertaking. ${creation [(2)+(3)] / release [(2)-(3)]/ invocation [(1)-(3)]} (**) The names of all the promoters, their shareholding in the target company and their pledged shareholding as on the reporting date should appear in the table irrespective of whether they are reporting on the date of event or not. PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED CIN: U24239MH1991PLC059995 [Showing first 8,000 characters — download PDF for full document]